GYRE
Under ReviewGyre Therapeutics Inc.
Healthcare · Biotechnology
$7.08
$0.04 (-0.56%)
Amanah Score™
0.0/5
Non-Compliant
Multi-dimensional score based on AAOIFI Standard 21 screening across debt, revenue purity, and interest exposure ratios.
Debt Ratio
••••
Sign up to see
Revenue Purity
••••
Sign up to see
Interest Exposure
••••
Sign up to see
Sign up free to see full ratio breakdowns, provider consensus, trend history, and AI-powered analysis.
Unlock Full Analysis — FreeWhat is AAOIFI Screening?
The Accounting and Auditing Organization for Islamic Financial Institutions (AAOIFI) sets the global standard for Shariah-compliant investing. Standard 21 defines quantitative thresholds that stocks must pass to be considered halal for Muslim investors.
Amanah screens every stock against these thresholds using data from 5 independent financial providers, then calculates a consensus-based Amanah Score™ that combines debt safety, revenue quality, and data confidence into a single 0–5 trust score.
Key Statistics
Market Cap$741M
P/E Ratio369.50
EPS—
Dividend Yield—
Beta—
52-Week High$11.78
52-Week Low$6.11
Want the full picture?
- Full AAOIFI ratio breakdown
- 5-provider data consensus
- AI compliance explainer
- Score trend tracking